Cargando…
How to expedite early‐phase SARS‐CoV‐2 vaccine trials in pandemic setting—A practical perspective
Autores principales: | van der Plas, Johan L., Roestenberg, Meta, Cohen, Adam F., Kamerling, Ingrid M.C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300705/ https://www.ncbi.nlm.nih.gov/pubmed/32557771 http://dx.doi.org/10.1111/bcp.14435 |
Ejemplares similares
-
Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season
por: Van Der Plas, Johan L., et al.
Publicado: (2019) -
Corrigendum: Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
por: Roestenberg, Meta, et al.
Publicado: (2019) -
Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
por: Roestenberg, Meta, et al.
Publicado: (2018) -
Assessment of Risks Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Experimental Human Infection Studies
por: Kuiper, Vincent P, et al.
Publicado: (2020) -
Accelerating vaccine trial conduct in a pandemic with a hot spot‐based inclusion strategy using trial and epidemic simulation
por: van der Plas, Johan L., et al.
Publicado: (2021)